PORTAL, HARVARD MEDICAL SCHOOL, BOSTON, MA, USA.
J Law Med Ethics. 2023;51(1):213-216. doi: 10.1017/jme.2023.58. Epub 2023 May 25.
The European Commission's proposal to address antimicrobial resistance using transferable exclusivity vouchers (TEVs) is fundamentally flawed. European policymakers and regulators should consider alternatives, such as better funding for basic and clinical research, use of advance market commitments funded by a pay-or-play tax, or enacting an EU Fund for Antibiotic Development.
欧盟委员会提出的利用可转让独占权凭证（TEVs）来解决抗微生物药物耐药性的建议存在根本性缺陷。欧洲政策制定者和监管机构应考虑其他替代方案，例如为基础和临床研究提供更好的资金、利用预付款制度的预付款市场承诺供资，或制定欧盟抗生素开发基金。
